

# NCPE Assessment

## Plain English Summary

November 2025

**Drug name:** Sparsentan (pronounced spar-SEN-tan) for the treatment of adults with primary immunoglobulin A nephropathy (IgAN) with a urine protein excretion  $\geq 1.0\text{g/day}$  (or urine protein-to-creatinine ratio  $\geq 0.75\text{g/g}$ )

**Brand name:** Filspari®

**HTA ID:** 24020

## What is the NCPE?

---

The National Centre for Pharmacoeconomics (NCPE) is a team of experts who look at the health benefits and costs of medicines. The HSE asks us to advise on whether or not a new medicine is good value for money. We give unbiased advice to help the HSE provide the most effective, safe and cost-effective (value for money) treatments for patients.

## How do we make our recommendations?

---

Our main focus is on the health benefits and cost effectiveness of a medicine. We look at the wider costs and health benefits associated with a new medicine, for example:

- Does the new medicine work better than other treatments available in Ireland?
- Is the new medicine easier to give or easier to take compared with other treatments available in Ireland?
- Does the new medicine reduce the need for patients to be hospitalised?
- Does the new medicine improve the quality of a patient's life over other treatments available in Ireland?
- Will the new medicine save resources elsewhere within the health system?

We review the information from clinical trials along with the cost and value for money data presented by the pharmaceutical company. We ask doctors and other healthcare professionals for advice about any health benefits of the new medicine compared with current treatments. We also ask patient organisations to send us their views on how the new drug may improve patients' day-to-day experience of living with a disease.

## What is sparsentan used for?

---

Spasentan is a medicine used to treat adults with primary immunoglobulin A nephropathy, a disease where the kidneys gradually stop working and might eventually fail, requiring patients to have dialysis (a process for removing unwanted substances or excess fluid from the blood) or a kidney transplant. In primary immunoglobulin A nephropathy, the cause of the disease is unknown. The medicine is to be used in people who have at least 1g of protein in their urine per day or a urine protein-to-creatinine ratio of at least 0.75g/g (another

measure of protein levels in the urine).

## **What recommendation has the NCPE made to the HSE?**

---

We have recommended that the HSE should consider not funding sparsentan unless its cost effectiveness (value for money) can be improved. The HSE will consider our recommendation and make the final decision about reimbursement (funding). When making the funding decision, the HSE will also consider the additional [criteria](#) outlined in the Health (Pricing and Supply of Medical Goods) Act 2013.

## **Why did we make this recommendation?**

---

After reviewing the data presented by the pharmaceutical company, we recommend that the HSE consider not providing sparsentan unless the HSE can agree a suitable price reduction with the pharmaceutical company. This is because we believe the medicine may work as well or better than other ways to manage primary immunoglobulin A nephropathy in the short-term, but we are unsure about how well the medicine works for patients who need long-term treatment. The current price of the medicine is too high compared to other ways to manage this condition, and we believe that the medicine is very poor value for money.

## **Next steps**

---

When the HSE receives our recommendation, it will look at all the relevant data about sparsentan. The HSE makes the final decision on reimbursement.

## **Where can I get more information?**

---

You can get more information about sparsentan from the following online options:

- the NCPE Technical Summary Document
- Filspari® European Public Assessment Report (EPAR) – [Medicine overview](#), or
- searching for sparsentan on our website ([www.ncpe.ie](http://www.ncpe.ie));
- searching for sparsentan on the European Medicines Agency (EMA) website ([www.ema.europa.eu](http://www.ema.europa.eu)).

Please refer to the NCPE website for updated information on the reimbursement status of this medicine